Cargando…
Sertindole in the Management of Schizophrenia
Nowadays, new schizophrenia treatments are more ambitious than ever, aiming not only to improve psychotic symptoms, but also quality of life and social reinsertion. Our objective is to briefly but critically review the diagnosis of schizophrenia, the atypical antipsychotics sertindole’s pharmacology...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663609/ https://www.ncbi.nlm.nih.gov/pubmed/23861640 http://dx.doi.org/10.4137/JCNSD.S5729 |
_version_ | 1782271007167348736 |
---|---|
author | Juruena, Mario F. de Sena, Eduardo Pondé de Oliveira, Irismar Reis |
author_facet | Juruena, Mario F. de Sena, Eduardo Pondé de Oliveira, Irismar Reis |
author_sort | Juruena, Mario F. |
collection | PubMed |
description | Nowadays, new schizophrenia treatments are more ambitious than ever, aiming not only to improve psychotic symptoms, but also quality of life and social reinsertion. Our objective is to briefly but critically review the diagnosis of schizophrenia, the atypical antipsychotics sertindole’s pharmacology, safety and status, and mainly evaluate the effects of sertindole compared with other second generation antipsychotics for people with schizophrenia and schizophrenia-like psychosis. In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT(2A), 5-HT(2C), dopamine D(2), and α(l) adrenergic receptors. Sertindole offers an alternative treatment option for refractory patients given its good EPS profile, favorable metabolic profile, and comparable efficacy to risperidone. Due to cardiovascular safety concerns, sertindole is available as a second-line choice for patients intolerant to other antipsychotic agents. Further clinical studies, mainly comparisons with other second-generation antipsychotic agents, are needed to define the role of sertindole in the treatment of schizophrenia. |
format | Online Article Text |
id | pubmed-3663609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-36636092013-07-16 Sertindole in the Management of Schizophrenia Juruena, Mario F. de Sena, Eduardo Pondé de Oliveira, Irismar Reis J Cent Nerv Syst Dis Review Nowadays, new schizophrenia treatments are more ambitious than ever, aiming not only to improve psychotic symptoms, but also quality of life and social reinsertion. Our objective is to briefly but critically review the diagnosis of schizophrenia, the atypical antipsychotics sertindole’s pharmacology, safety and status, and mainly evaluate the effects of sertindole compared with other second generation antipsychotics for people with schizophrenia and schizophrenia-like psychosis. In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT(2A), 5-HT(2C), dopamine D(2), and α(l) adrenergic receptors. Sertindole offers an alternative treatment option for refractory patients given its good EPS profile, favorable metabolic profile, and comparable efficacy to risperidone. Due to cardiovascular safety concerns, sertindole is available as a second-line choice for patients intolerant to other antipsychotic agents. Further clinical studies, mainly comparisons with other second-generation antipsychotic agents, are needed to define the role of sertindole in the treatment of schizophrenia. Libertas Academica 2011-05-17 /pmc/articles/PMC3663609/ /pubmed/23861640 http://dx.doi.org/10.4137/JCNSD.S5729 Text en © 2011 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
spellingShingle | Review Juruena, Mario F. de Sena, Eduardo Pondé de Oliveira, Irismar Reis Sertindole in the Management of Schizophrenia |
title | Sertindole in the Management of Schizophrenia |
title_full | Sertindole in the Management of Schizophrenia |
title_fullStr | Sertindole in the Management of Schizophrenia |
title_full_unstemmed | Sertindole in the Management of Schizophrenia |
title_short | Sertindole in the Management of Schizophrenia |
title_sort | sertindole in the management of schizophrenia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663609/ https://www.ncbi.nlm.nih.gov/pubmed/23861640 http://dx.doi.org/10.4137/JCNSD.S5729 |
work_keys_str_mv | AT juruenamariof sertindoleinthemanagementofschizophrenia AT desenaeduardoponde sertindoleinthemanagementofschizophrenia AT deoliveirairismarreis sertindoleinthemanagementofschizophrenia |